{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-23-000022","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.860215+00:00","generated_at":"2026-06-12T10:32:58.281616+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Gilead Q2 revenue $6.6B (+5%); EPS down to $0.83 on $525M legal charge; guidance raised ex-Veklury","bullets":["Total product sales ex-Veklury up 11% to $6.3B; HIV sales up 9% to $4.6B, Biktarvy up 17% to $3.0B.","Oncology sales up 38% to $728M; Trodelvy up 63% to $260M, Cell Therapy up 27% to $469M.","GAAP diluted EPS $0.83 vs $0.91 YoY; non-GAAP EPS $1.34 vs $1.58; impact of $0.32 from $525M HIV antitrust litigation accrual.","Full-year 2023 guidance: total product sales raised to $26.3-26.7B (prev $26.0-26.5B); ex-Veklury raised to $24.6-25.0B; Veklury lowered to ~$1.7B (prev ~$2.0B).","GAAP EPS guidance lowered to $4.50-4.85 (prev $4.75-5.15); non-GAAP EPS lowered to $6.45-6.80 (prev $6.60-7.00)."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-23-000022","json":"https://secwatch.observer/filing/0000882095-23-000022.json","markdown":"https://secwatch.observer/filing/0000882095-23-000022.md","text":"https://secwatch.observer/filing/0000882095-23-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000022/0000882095-23-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000022/gild-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T10:32:58.281616+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"639b601d2a72c56286b13fe2cf1effeff123bd72","claim":"GILEAD SCIENCES, INC. reported the quarter ended June 30, 2023 results: revenue $6.6 billion, EPS $0.83 per share (GAAP diluted).","evidence_excerpt":"Total second quarter 2023 revenue increased 5% to $6.6 billion compared to the same period in 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000022/0000882095-23-000022-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$6.6 billion"},{"label":"EPS","value":"$0.83 per share (GAAP diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}